Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Frequently asked questions
What sector does Onconetix Inc (ONCO) operate in?
Onconetix Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Onconetix Inc (ONCO) current stock price?
As of the latest data, Onconetix Inc stock price is $0.38, with a previous close of $0.40. Onconetix Inc lost -$0.02 in the last trading session, representing a -4.71% loss.
What is Onconetix Inc (ONCO) current market capitalization?
Onconetix Inc market cap is approximately 1.67 million.
What is Onconetix Inc (ONCO) Earnings Per Share (EPS)?
The trailing EPS is $749.08.
What is Onconetix Inc (ONCO) Price-to-Earnings (P/E) ratio?
Onconetix Inc current P/E ratio is 0.
What is Onconetix Inc (ONCO) EBITDA?
Onconetix Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.86 million.
Does Onconetix Inc (ONCO) pay dividends?
No. Onconetix Inc does not pay a dividend.
What is Onconetix Inc (ONCO) beta (volatility) score?
Onconetix Inc has a beta of 2.675, indicating very high volatility compared to the market.
